natgillin/translations-raw huggingface dataset:
Tabulated list of adverse reactions in non-small cell lung cancer for docetaxel 75 mg/m2 in combination with cisplatin 
Tablični popis nuspojava kod karcinoma nemalih stanica pluća za docetaksel 75 mg/m² u kombinaciji s cisplatinom
Tabulated list of adverse reactions in breast cancer for docetaxel 100 mg/m2 in combination with trastuzumab 
Tablični popis nuspojava kod karcinoma dojke za docetaksel 100 mg/m² u kombinaciji s trastuzumabom
Neutropenia (G3/4: 83.2%); Thrombocytopenia (G3/4: Febrile neutropenia 
Poremećaji krvi i limfnog sustava neutropenija (G3/4: 83,5%); anemija (G3/4: 12,4%); trombocitopenija (G3/4: febrilna neutropenija
Docetaxel Accord in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. 
Docetaxel Accord u kombinaciji s doksorubicinom indiciran je za liječenje bolesnika s lokalno uznapredovalim ili metastatskim karcinomom dojke koji nisu ranije liječeni citostaticima za tu bolest.
Docetaxel in combination with platinum agents in chemotherapy-naïve patients 
Docetaksel u kombinaciji s derivatima platine u bolesnika koji nisu ranije primali kemoterapiju
Description of selected adverse reactions in gastric adenocarcinoma cancer for docetaxel 75 mg/m2 in combination with cisplatin and 5-fluorouracil 
Opis odabranih nuspojava za docetaksel 75 mg/m² u kombinaciji s cisplatinom i 5-fluorouracilom u terapiji adenokarcinoma želuca
Tabulated list of adverse reactions in breast cancer for docetaxel 75 mg/m2 in combination with doxorubicin 
Tablični popis nuspojava kod karcinoma dojke za docetaksel 75 mg/m² u kombinaciji s doksorubicinom
Dysgeusia/Parosmia (G3/4: 0.4%); 
Česte nuspojave klijetke (G3/4: 0,3%)
Diarrhoea (G3/4: 1.2%); 
bol izazvana karcinomom (G3/4: 1,2%)
Dizziness (G3/4: Peripheral motor neuropathy (G3/4: 
Poremećaji živčanog sustava disgeuzija (G3/4: periferna senzorna neuropatija (G3/4:
Stomatitis (G3/4: 1.7%); Vomiting (G3/4: 0.8%); 
Poremećaji probavnog sustava mučnina (G3/4: 3,3%); stomatitis (G3/4: 1,7%); povraćanje (G3/4: 0,8%); proljev (G3/4: 1,7%)
Lacrimation increased (G3/4: 
pojačano suzenje (G3/4:
patients were randomised to receive either docetaxel 75 mg/m2 administered 1-hour after doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 (TAC arm), or doxorubicin 50 mg/m2 followed by fluorouracil 500 mg/m2 and cyclosphosphamide 500 mg/m2 (FAC arm). 
Nakon stratifikacije prema broju pozitivnih limfnih čvorova (1-3, 4+), randomiziran je 1491 bolesnik u skupine koje će primati ili docetaksel 75 mg/m2 primijenjen jedan sat nakon doksorubicina 50 mg/m2 i ciklofosfamida 500 mg/m2 (TAC skupina) ili doksorubicin 50 mg/m2 nakon kojeg slijedi fluorouracil 500 mg/m2 i ciklofosfamid 500 mg (FAC skupina).
In study GEICAM 9805 peripheral oedema that started during the treatment period persisted into the follow-up period in 4 patients (0.8%) in TAC arm and in 2 patients (0.4%) in FAC arm. At the end of the follow-up period (median follow-up time of 10 years and 5 months), no patients (0%) in TAC arm had peripheral oedema and it was observed to be ongoing in 1 patient (0.2%) in FAC arm. 
U ispitivanju GEICAM 9805 periferni edem koji je počeo tijekom perioda liječenja te je bio prisutan u periodu praćenja u 4 bolesnika (0,8%) u TAC skupini te u 2 bolesnika (0,4%) u FAC skupini.
Alopecia; Erythema; Rash; Nail disorders 
Poremećaji kože i potkožnog tkiva alopecija;eritem; osip; poremećaji noktiju
In GEICAM 9805 study alopecia that started during the treatment period and persisted into the follow-up period was observed to be ongoing in 49 patients (9.2 %) in TAC arm and 35 patients (6.7 %) in FAC arm. Alopecia related to study drug started or worsened during the follow-up period in 42 patients (7.9 %) in TAC arm and 30 patients (5.8 %) in FAC arm. At the end of the follow-up period (median follow-up time of 10 years and 5 months), alopecia was observed to be ongoing in 3 patients (0.6%) in TAC arm, and in 1 patient (0.2%) in FAC arm. 
U GEICAM 9805 ispitivanju, koja je počela tijekom perioda liječenja i dalje bila prisutna tijekom perioda praćenja zabilježena je u 49 bolesnika (9,2%) u TAC skupini i u 35 bolesnika (6,7%) u FAC skupini.
In a phase III study, 1218 patients with unresectable stage IIIB or IV NSCLC, with KPS of 70% or greater, and who did not receive previous chemotherapy for this condition, were randomised to either docetaxel (T) 75 mg/m2 as a 1 hour infusion immediately followed by cisplatin (Cis) 75 mg/m2 over 30-60 minutes every 3 weeks (TCis), docetaxel 75 mg/m2 as a 1 hour infusion in combination with carboplatin (AUC 6 mg/ml.min) over 30-60 minutes every 3 weeks, or vinorelbine (V) 25 mg/m2 administered over 6-10 minutes on days 1, 8, 15, 22 followed by cisplatin 100 mg/m2 administered on day 1 of cycles repeated every 4 weeks (VCis). 
[engl. area under curve] 6 mg/ml u min) tijekom 30-60 min svaka tri tjedna ili vinorelbin (V) 25 mg/m2 primijenjen tijekom 6 do 10 minuta na dan 1, 8, 15, 22, nakon čega je slijedilo davanje cisplatine 100 mg/m2 na dan 1 ciklusa koji se ponavljao svaka 4 tjedna (VCis).
Dyspnoea; 
bolesnika.
Patients who experience Grade 3 or 4 stomatitis should have their dose decreased to 60 mg/m2. 
ili 4 treba smanjiti dozu na 60 mg/m2.
Tabulated list of adverse reactions in breast cancer for docetaxel 75 mg/m2 in combination with capecitabine 
Tablični popis nuspojava kod karcinoma dojke za docetaksel 75 mg/m² u kombinaciji s kapecitabinom
• 1,312 and 121 patients who received 100 mg/m2 and 75 mg/m2 of docetaxel as a single agent respectively. 
Nuspojave koje su moguće ili vjerojatno povezane s primjenom docetaksela zabilježene su u: • 1312 bolesnika koji su primali 100 mg/m2 i 121 bolesnika koji su primali 75 mg/m2
Nail disorders (severe: Skin reaction (G3/4: 
Poremećaji kože i potkožnog tkiva alopecija; poremećaji noktiju (teški: 0,7%) kožna reakcija (G3/4:
Peripheral sensory neuropathy (G3: 4.1%); Peripheral motor neuropathy (G3/4: 4%); Dysgeusia (severe: 0.07%) 
Poremećaji živčanog sustava periferna senzorna neuropatija (G3/4: 1,2%); disgeuzija (G3/4: 0%)
Esophagitis/dysphagia/ odynophagia (G3/4: 
Poremećaji metabolizma i prehrane anoreksija (G3/4:
Peripheral sensory neuropathy (G3/4: 0.6%) 
periferna motorna neuropatija (G3/4: 0,4%)
Patients with operable node-positive breast cancer (TAX 316) Data from a multicentre open-label randomised study support the use of docetaxel for the adjuvant treatment of patients with operable node-positive breast cancer and KPS ≥ 80%, between 18 and 70 years of age. 
Docetaksel u kombinaciji s doksorubicinom i ciklofosfamidom: adjuvantno liječenje Bolesnici s operabilnim karcinomom dojke i pozitivnim limfnim čvorovima (TAX 316) Podaci iz multicentričnog, otvorenog, randomiziranog ispitivanja podupiru primjenu docetaksela za adjuvantno liječenje bolesnika s operabilnim karcinomom dojke i pozitivnim limfnim čvorovima te s KPS (engl.
256 patients were randomised to treatment with docetaxel alone (100 mg/m2 as a 1 hour intravenous infusion every 3 weeks). 
Za liječenje docetakselom u monoterapiji (100 mg/m2 u obliku jednosatne intravenske infuzije svaka tri tjedna) bilo je randomizirano 256
Gastrointestinal pain (G3/4: 1.2%); 
gastrointestinalna bol (G3/4: 1,2%); gastrointestinalno krvarenje (G3/4:
Myalgia (G3/4: 2%); Arthralgia (G3/4: 1%) 
Poremećaji mišićno-koštanog sustava i vezivnog tkiva mijalgija (G3/4: 2%) artralgija (G3/4: 1%)
Myalgia (G3/4: 0.7%); Arthralgia (G3/4: 
Poremećaji mišićnokoštanog sustava i vezivnog tkiva mijalgija (G3/4: 0,7%) artralgija (G3/4: 0,2%)
Fluid retention (severe: Asthenia (severe: 11.2%); Pain 
Opći poremećaji i reakcije na mjestu primjene astenija (teška: 8,1%); retencija tekućine (teška: 1,2%); bol reakcija na mjestu primjene infuzije
Thrombocytopenia (G3/4: Febrile neutropenia 
trombocitopenija (G3/4: 0,6%); febrilna neutropenija
Patients on the docetaxel arm received docetaxel (T) 75 mg/m2 followed by cisplatin (P) 75 mg/m2 followed by 5-fluorouracil (F) 750 mg/m2 per day as a continuous infusion for 5 days. 
Bolesnici u docetaksel skupini primali su docetaksel (T) 75 mg/m2 nakon čega je slijedio cisplatin (P) 75 mg/m2 te 5-fluorouracil (F) 750 mg/m2 dnevno u obliku kontinuirane infuzije tijekom 5 dana, Ovaj protokol bio je primjenjivan svaka tri tjedna, tijekom 4 ciklusa u slučaju da je barem najmanji odgovor (≥ 25% smanjenje dvodimenzionalno mjerene veličine tumora) bio primijećen nakon 2 ciklusa.
Arthralgia (G3/4: 0.3%); Myalgia (G3/4: 0.3%) 
kožna toksičnost (G3/4: 0,6%) poremećaji noktiju (G3/4: 0,4%)
Neutropenia (G4: 76.4%); Anaemia (G3/4: 8.9%); 
76,4%); anemija (G3/4: 8,9%); febrilna neutropenija trombocitopenija (G4:
Peripheral sensory neuropathy (G3/4: 
Poremećaji živčanog sustava periferna senzorna neuropatija (G 3:
Number of patients Median survival (months) 95% CI 
Medijan preživljenja (mjeseci) 95% CI
Anaemia (G3/4: 6.9%); Thrombocytopenia (G4: 0.5%) 
Poremećaji krvi i limfnog sustava neutropenija (G4: anemija (G3/4: 6,9%); trombocitopenija (G4: 0,5%)
Stomatitis/Pharyngitis (G3/4: Vomiting (G3/4: 1.2%) 
Poremećaji uha i labirinta oštećenje sluha (G3/4:1,2%)
Musculoskeletal and 
fluorouracilom.
Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion Clear glass (type I) vial with fluorotec plus (ethylene tetrafluoroethylene film) rubber stopper and aluminium seal and a red flip-off cap, containing 4 ml of concentrate. 
Prozirna staklena bočica (staklo tip I), s fluorotec plus (etilen-tetrafluoroetilen film) gumenim čepom i aluminijskim zatvaračem i crvenom „flip-off „ zaštitnom kapicom, koja sadrži 4 ml koncentrata.
Hand-foot syndrome (G3/4: Alopecia (G3/4: 6%); 
Poremećaji kože i potkožnog tkiva sindrom šaka-stopalo (G 3/4: alopecija (G 3/4: 6%); poremećaji noktiju (G 3/4: 2%)
Tabulated list of adverse reactions in non-small cell lung cancer for docetaxel 75 mg/m2 single agent 
Tablični popis nuspojava kod karcinoma nemalih stanica pluća za docetaksel 75 mg/m² u monoterapiji
Arrhythmia (G3/4: 
Srčani poremećaji aritmija (G3/4:
Stomatitis (G3/4: 18%); Diarrhoea (G3/4: 14%); Nausea (G3/4: 6%); 
Poremećaji probavnog sustava mučnina (G3/4: 9,6%); povraćanje (G3/4: proljev (G3/4: 6,4%); stomatitis (G3/4: 2%)
G3/4 AST increased (< 3%); G3/4 ALT increased (< 2%) 
G3/4 povećanje bilirubina u krvi (<5%); G3/4 povećanje alkalne fosfataze u krvi (<4%); G3/4 povećanje AST
Date of first authorisation:12 June 2009 
Datum prvog odobrenja: 12. lipanj 2009.
Approximately 5% of patients can be expected to experience adverse reactions . 
Očekuje se da će otprilike 5% bolesnika osjetiti nuspojave.
The absolute bioavailability from the tablet was found to be about 77 %. 
Apsolutna bioraspoloživost iz tablete iznosi oko 77%.
Do not take a double dose to make up for the forgotten dose. 
Nemojte uzeti dvostruku dozu kako biste nadoknadili propuštenu dozu.
If you take more PANTECTA Control than you should Tell your doctor or pharmacist if you have taken more than the recommended dose. 
Ako uzmete više PANTECTA Control nego što ste trebali Obavijestite liječnika ili ljekarnika ako ste uzeli više od preporučene doze.
You should not take this medicine if you are pregnant or while-breastfeeding. 
Ne uzimajte ovaj lijek ako ste trudni ili dojite.
You must not use PANTECTA Control if you are taking atazanavir. 
Ne smijete koristiti PANTECTA Control ako uzimate atazanavir.
PANTECTA Control is not recommended for use in children and adolescents below 18 years of age due to insufficient data on safety and efficacy. 
PANTECTA Control se ne preporučuje za primjenu u djece i adolescenata u dobi ispod 18 godina jer nema dovoljno podataka o sigurnosti i djelotvornosti.
Always take this medicine exactly as described in this leaflet or as your doctor or pharmacist have told you. 
Uvijek uzimajte ovaj lijek točno onako kako je opisano u ovoj Uputi ili kako su Vam rekli Vaš liječnik ili ljekarnik.
You must talk to a doctor if you do not feel better or if you feel worse after 2 weeks. 
Obavezno se morate obratiti liječniku ako se ne osjećate bolje ili ako se osjećate lošije nakon 2 tjedna.
PANTECTA Control has no or negligible influence on the ability to drive and use machines. 
PANTECTA Control ne utječe ili neznatno utječe na sposobnost upravljanja vozilima ili rada sa strojevima.
What PANTECTA Control is and what it is used for 
Što je PANTECTA Control i za što se koristi
Especially medicines containing one of the following active substances: - atazanavir (used to treat HIV-infection). 
Naročito lijekova koji sadrže sljedeće djelatne tvari: - atazanavir (koristi se za liječenje HIV-infekcije).
PANTECTA Control 20 mg gastro-resistant tablets should not be chewed or crushed, and should be swallowed whole with liquid before a meal. 
PANTECTA Control 20 mg želučanootporne tablete se ne smiju žvakati ni lomiti, već ih se mora progutati cijele s tekućinom prije obroka.
- The other ingredients are: 
Ostale nuspojave uključuju:
Hallucination; Confusion (especially in pre-disposed patients, as well as the aggravation of these symptoms in case of pre-existence) 
halucinacije; konfuzija (posebno u predisponiranih bolesnika, kao i pogoršanje tih simptoma ako su već bili prisutni)
PANTECTA Control is available in Alu/Alu blisters with or without cardboard reinforcement. 
PANTECTA Control je dostupan u Al/Al blisterima sa ili bez kartonskog pojačanja.
It has been shown that co-administration of atazanavir 300 mg/ritonavir 100 mg with omeprazole (40 mg once daily) or atazanavir 400 mg with lansoprazole (60 mg single dose) to healthy volunteers resulted in a substantial reduction in the bioavailability of atazanavir. 
Dokazano je da istodobna primjena atazanavira 300 mg/ritonavira 100 mg s omeprazolom (40 mg jednom dnevno) ili atazanavira 400 mg s lanzoprazolom (jednokratna doza od 60 mg) kod zdravih dobrovoljaca rezultira značajnim smanjenjem bioraspoloživosti atazanavira.
Stop taking PANTECTA Control when you are completely symptom-free. 
Prestanite uzimati PANTECTA Control kada nastupi potpuno povlačenje simptoma.
What PANTECTA Control is and what it is used for What you need to know before you take PANTECTA Control How to take PANTECTA Control Possible side effects 
Što je PANTECTA Control i za što se koristi Što morate znati prije nego počnete uzimati PANTECTA Control Kako uzimati PANTECTA Control Moguće nuspojave
Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data). 
Unutar sljedeće tablice nuspojave su razvrstane prema MedDRA klasifikaciji učestalosti: Vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000), vrlo rijetko (< 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
How to store PANTECTA Control Contents of the pack and other information 
Kako čuvati PANTECTA Control Sadržaj pakiranja i druge informacije
PANTECTA Control should not be used by children and adolescents under 18 years of age due to a lack of safety information in this younger age group.. 
PANTECTA Control ne smiju koristiti djeca i mladi u dobi do 18 godina jer ne postoje podaci o sigurnosti primjene u ovoj mlađoj dobnoj skupini.
Investigations revealed no evidence of impaired fertility or teratogenic effects. 
Istraživanjima nisu otkriveni nikakvi dokazi oštećenja plodnosti ili teratogeni učinci.
This may cause you symptoms such as a painful burning sensation in the chest rising up to the throat (heartburn) and a sour taste in the mouth (acid regurgitation). 
To može uzrokovati simptome kao što su bolan osjećaj pečenja u prsnom košu koji se uzdiže do grla (žgaravica) i kiseli okus u ustima (vraćanje kiseline).
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/. 
Podrobnije informacije o ovom lijeku dostupne su na web stranicama Europske agencije za lijekove http://www.ema.europa.eu/
The absorption of atazanavir is pH-dependent. 
Apsorpcija atazanavira je ovisna o pH.
What PANTECTA Control contains - The active substance is pantoprazole. 
Što PANTECTA Control sadrži - Djelatna tvar je pantoprazol.
Uncommon Rare 
Vrlo rijetke Nepoznato
Do not take PANTECTA Control with other medicines which limit the amount of acid produced in your stomach, such as another proton pump inhibitor (omeprazole, lansoprazole or rabeprazole) or an H2 antagonist (e.g. ranitidine, famotidine). 
Ne uzimajte PANTECTA Control s drugim lijekovima koji ograničavaju količinu proizvodnje želučane kiseline, kao što su drugi inhibitor protonske pumpe (omeprazol, lanzoprazol ili rabeprazol) ili H2 antagonist (npr. ranitidin, famotidin).
- You should not take PANTECTA Control tablets for more than 4 weeks without consulting a doctor. 
- Ne smijete uzimati PANTECTA Control tablete dulje od 4 tjedna bez savjetovanja s liječnikom.
In these cases, malignancy should be excluded. 
takvim je slučajevima potrebno isključiti maligne bolesti.
PANTECTA Control contains the active substance pantoprazole, which blocks the ‘pump' that produces stomach acid. 
PANTECTA Control sadrži djelatnu tvar pantoprazol, koja blokira „pumpu“ koja proizvodi želučanu kiselinu.
What you need to know before you take PANTECTA Control 
Što morate znati prije nego počnete uzimati PANTECTA Control
PANTECTA Control may reduce the absorption of active substances whose bioavailability is dependent on the gastric pH (e.g. ketoconazole). 
PANTECTA Control može smanjiti apsorpciju djelatnih tvari čija bioraspoloživost ovisi o pH želuca (npr. ketokonazol).
- You must talk to a doctor if you do not feel better or if you feel worse after 2 weeks. 
Pogledajte dio 4. - Obavezno se morate obratiti liječniku ako se ne osjećate bolje ili ako se osjećate lošije nakon 2
Therefore, pantoprazole must not be co-administered with atazanavir (see section 4.3). 
Zato se pantoprazol ne smije primjenjivati istodobno s atazanavirom (vidjeti dio 4.3).
Co-administration with atazanavir (see section 4.5). 
Istodobna primjena s atazanavirom (vidjeti dio 4.5).
Stevens-Johnson syndrome; Lyell syndrome; 
Stevens-Johnsonov sindrom; Lyellov sindrom; erythema multiforme; fotoosjetljivost
If you forget to take PANTECTA Control 
Ako zaboravite uzeti PANTECTA Control
- if you have been treated for heartburn or indigestion continuously for 4 or more weeks - if you are over 55 years old and taking non-prescription indigestion treatment on a daily basis - if you are over 55 years old with any new or recently changed reflux symptoms - if you have previously had a gastric ulcer or stomach surgery - if you have liver problems or jaundice (yellowing of skin or eyes) - if you regularly see your doctor for serious complaints or conditions - if you are due to have an endoscopy or a breath test called a C-urea test. 
- ako ste stariji od 55 godina i svakodnevno uzimate lijekove za probavne smetnje koji se izdaju bez recepta - ako ste stariji od 55 godina i imate bilo kakve nove ili nedavno promijenjene simptome refluksa - ako ste imali čir na želucu ili operaciju želuca - ako imate probleme s jetrom ili žuticu (žutilo kože ili očiju) - ako redovno posjećujete liječnika zbog neke ozbiljne bolesti ili stanja - ako ste naručeni na endoskopiju ili C-urea izdisajni test.
Animal studies have shown excretion of pantoprazole in breast milk. 
Ispitivanja na životinjama su pokazala da se pantoprazol izlučuje u mlijeku.
However, you may take PANTECTA Control with antacids (e.g. magaldrate, alginic acid, sodium bicarbonate, aluminium hydroxide, magnesium carbonate, or combinations thereof), if needed. 
Ako je potrebno, PANTECTA Control možete uzimati s antacidima (npr. megaldrat, alginatna kiselina, natrijev bikarbonat, aluminijev hidroksid, magnezijev karbonat ili kombinacije navedenih).
Other medicines and PANTECTA Control 
Drugi lijekovi i PANTECTA Control
What PANTECTA Control looks like and contents of the pack The gastro-resistant tablets are yellow, oval, biconvex film-coated tablets imprinted with “P20” on one side. 
Kako PANTECTA Control izgleda i sadržaj pakiranja Želučanootporne tablete su žute, ovalne, bikonveksne, filmom obložene tablete sa smeđom oznakom "P20" na jednoj strani.
Do not take PANTECTA Control: - if you are allergic to pantoprazole or to any of the other ingredients of this medicine (listed in section 6). 
Ne uzimajte PANTECTA Control: - ako ste alergični na pantoprazol ili bilo koji sastojak ovog lijeka (navedeno u dijelu 6) - ako uzimate lijekove koji sadrže atazanavir (za liječenje infekcije HIV-om).
It is unknown whether pantoprazole is excreted in human breast milk. 
Nije poznato izlučuje li se pantoprazol u majčino mlijeko u ljudi.
Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines PANTECTA Control may stop certain other medicines from working properly. 
Obavijestite liječnika ili ljekarnika ukoliko koristite, nedavno ste koristili ili biste mogli koristiti bilo koje druge lijekove.
Tell your doctor immediately, before or after taking this medicine, if you notice any of the following symptoms, which could be a sign of another, more serious, disease: - an unintentional loss of weight (not related to a diet or an exercise programme) - vomiting, particularly if repeated - vomiting blood; this may appear as dark coffee grounds in your vomit - you notice blood in your stools; which may be black or tarry in appearance - difficulty in swallowing or pain when swallowing - you look pale and feel weak (anaemia) - chest pain - stomach pain - severe and/or persistent diarrhoea, because this medicine has been associated with a small increase in infectious diarrhoea. 
Odmah obavijestite svog liječnika, prije ili nakon uzimanja ovog lijeka, ako primijetite neki od sljedećih simptoma koji može biti znak druge, ozbiljnije bolesti: - nenamjeran gubitak težine (koji nije vezan uz dijetu ili program tjelovježbe) - povraćanje, osobito ako se ponavlja - povraćanje krvi, što možete primijetiti u obliku tamnih zrnaca veličine zrna kave - krv u stolici, koja može biti crna ili poput katrana - teškoće pri gutanju ili bol pri gutanju - bljedoća ili osjećaj slabosti (anemija) - bol u prsnom košu - bol u trbuhu - težak i/ili stalan proljev, jer je ovaj lijek povezan sa malim porastom zaraznog proljeva.
‘Other medicines and PANTECTA Control'. 
Pogledajte 'Ostali lijekovi i PANTECTA Control'.
In animal studies (rats) 5 mg/kg was the observed NOAEL (No Observed Adverse Effect Level) for embryotoxicity. 
U ispitivanjima na životinjama (štakori), 5 mg/kg je bila najviša doza koja ne uzrokuje embriotoksičnost.
Pharmacotherapeutic group: : Drugs for acid related disorders,Proton pump inhibitors, ATC code: A02BC02 
Inhibitori protonske pumpe, ATK oznaka: A02BC02
Do not use this medicine after the expiry date, which is stated on the carton and the blister after ‘EXP'. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i na blisteru iza 'Rok valjanosti'.
- Frequency not known: hallucination, confusion (especially in patients with a history of these symptoms); decreased level of sodium in blood; decreased level of magnesium in blood. 
Nepoznata učestalost: halucinacije, smetenost (pogotovo kod bolesnika koji su već imali te simptome), smanjenje razine natrija u krvi; smanjenje razine magnezija u krvi.
- Very rare side effects (may affect up to 1 in 10,000 people): disorientation; reduction in the number of blood platelets, which may cause you to bleed or bruise more than normal; reduction in the number of white blood cells, which may lead to more frequent infections; coexisting abnormal reduction in the number of red and white blood cells, as well as platelets (seen in blood tests). 
- Vrlo rijetke nuspojave (mogu se javiti kod do 1 na 10 000 osoba): dezorijentiranost; smanjenje broja krvnih pločica što može uzrokovati neuobičajena krvarenja i stvaranja modrica; smanjenje broja bijelih krvnih stanica što može dovesti do učestalih infekcija; istovremeno abnormalno smanjenje broja crvenih i bijelih krvnih stanica, te krvnih pločica (vidljivo na krvnim pretragama).
This leaflet was last revised in {MM/YYYY} 
Uputa je zadnji puta revidirana u MM/GGGG